Abstract
The kidney-specific gene UMOD encodes for uromodulin, the most abundant protein excreted in normal urine. Rare, large-effect variants in UMOD cause autosomal dominant tubulointerstitial kidney disease (ADTKD) while common, low-effect variants strongly associate with kidney function and risk of chronic kidney disease (CKD) in the general population. It is unknown whether intermediate-effect variants in UMOD contribute to CKD. Here, candidate intermediate-effect UMOD variants were identified using large population and ADTKD cohorts. Biological and phenotypical effects were investigated using cell models, in silico simulations and international databases and biobanks. Eight UMOD missense variants reported in ADTKD are present in gnomAD with MAF ranging from 10−5 to 10−3. Among them, the missense variant p.Thr62Pro is detected in ∼1/1,000 individuals of European ancestry, shows incomplete penetrance but a high genetic load in familial clusters of CKD and is associated with kidney failure in the 100,000 Genomes Project (OR 3.99; 1.84-8.98) and the UK Biobank (OR 4.12; 1.32-12.85). Compared to canonical ADTKD mutations, the p.Thr62Pro carriers displayed reduced disease severity, with slower progression of CKD, intermediate reduction of urinary UMOD levels, in line with an intermediate trafficking defect in vitro. Identification of an intermediate-effect UMOD variant completes the spectrum of UMOD-associated kidney diseases and provides novel insights into the mechanisms of ADTKD and the genetic architecture of CKD.
Significance Statement The genetic architecture of chronic kidney disease (CKD) remains incompletely understood. Variants in the kidney-specific gene UMOD cause autosomal dominant tubulointerstitial kidney disease (ADTKD) and are associated with kidney function and risk of CKD in the general population. Here, we identified an intermediate-effect variant, p.Thr62Pro, detected in ∼1:1,000 individuals of European ancestry, that showed a high genetic load in familial clusters of CKD and was associated with an OR of ∼4 for kidney failure in the 100,000 Genomes Project and the UK Biobank. Compared to canonical ADTKD mutations, p.Thr62Pro carriers displayed reduced disease severity and an intermediate trafficking defect. These findings complete the spectrum of UMOD-associated kidney diseases and provide a paradigm for the genetic contribution to CKD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
EO is supported by an Early Postdoc Mobility-Stipendium of the Swiss National Science Foundation (P2ZHP3_195181) and a Kidney Research UK grant Paed_RP_001_20180925, the Fonds National de la Recherche Luxembourg (grant 6903109) and the University Research Priority Program "Integrative Human Physiology, ZIHP" of the University of Zurich. MW is supported by Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 387509280 - SFB 1350, TP C4. The work of AK was supported by German Research Foundation (DFG) grant KO 3598/5-1, DFG - Project-ID 431984000 - SFB 1453. ADK was supported by a grant from the University of Zurich (Forschungskredit FK-14-035). EAEE is funded by the Royal College of Surgeons in Ireland Blackrock Clinic StAR MD. OD is supported by the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 860977, the European Reference Network for Rare Kidney Diseases (project 739532), the Swiss National Science Foundation's National Center of Competence in Research Kidney Control of Homeostasis program, the Swiss National Science Foundation (grant 310030-189044, the Gebert-Ruef Foundation for research on ADTKD-UMOD and the University Research Priority Program (URPP) ITINERARE at the University of Zurich. KK, SK and AJB were supported by grant NU21-07-00033 from the Ministry of Health of the Czech Republic. LR is supported by the Italian Ministry of Health (RF-2010-2319394 and RF-2016-02362623). JAS is supported by Kidney Research UK and the Northern Counties Kidney Research Fund. The 100,000 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. UK Biobank is supported by its founding funders the Wellcome Trust and UK Medical Research Council, as well as the Department of Health, Scottish Government, the Northwest Regional Development Agency, British Heart Foundation and Cancer Research UK. The GCKD study was funded by the German Ministry of Research and Education (Bundesminsterium fuer Bildung und Forschung, BMBF, grant number 01ER0804, K.U.E.); by the Foundation KfH Stiftung Praeventivmedizin and by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - Projektnummer 246781735 - SFB 1140; and by grants provided by Bayer, Fresenius Medical Care and Amgen. Genotyping was supported by Bayer Pharma AG. uUMOD measurements in GCKD were supported by the Swiss National Centre of Competence in Research Kidney Control of Homeostasis program and the Swiss National Science Foundation grant 310030_189044.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Informed and written consent was obtained from all participants and individual-level data was de-identified. All methods were carried out in accordance with approved guidelines and the Declaration of Helsinki. The 100,000 Genomes research and clinical project model and its informed consent process has been approved by the United Kingdom National Research Ethics Service Research Ethics Committee for East of England - Cambridge South Research Ethics Committee (https://www.genomicsengland.co.uk/about-genomics-england/the-100000-genomes-project/)(Ref 14/EE/1112). Ethics approval for the UK Biobank study was obtained from the United Kingdom North West Centre for Research Ethics Committee (approval number 11/NW/0382) (https://www.ukbiobank.ac.uk/). The German Chronic Kidney Disease Cohort was approved by the ethics commission of the Friedrich-Alexander-Universitaet Erlangen-Nuernberg, Germany (Nr 3831) and by the ethics committees of all participating institutions and registered in the national registry for clinical studies (Deutsches Register Klinischer Studien 00003971) (https://www.gckd.de/). The ADTKD cohort study was approved by the institutional review board of the Wake Forest School of Medicine, North Carolina, USA (Wake Forest University Health Sciences IRB00000352 "Characteristics of Individuals with Inherited Kidney Disease"), the Institutional review board of the Universite Catholique de Louvain (UCL) Medical School and Saint Luc University Hospital, Belgium (2011/04MAI/184) and the European Community's Seventh Framework Program "European Consortium for High-Throughput Research in Rare Kidney Diseases (EURenOmics)" Ethics Advisory Board. Further institutions involved in human participant research received local IRB approval as detailed in Table S8.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵18 List of authors and their affiliations appears in the supplementary information
Competing Interest Statement: The authors declare no potential conflict of interest relevant to this article.
Data Availability
The data that support the findings of this study are available from the article and the supplementary files, through The Human Gene Mutation Database at http://www.hgmd.cf.ac.uk/ac/index.php and PubMed at https://pubmed.ncbi.nlm.nih.gov. Data presented here were derived from the following resources available in the public domain: The Genome Aggregation Database v2.1.1 (https://gnomad.broadinstitute.org/) and Ensembl (release 100): (https://www.ensembl.org/index.html).
